The A53T alpha-synuclein transgenic mouse model is a genetic model of Parkinson's disease that expresses the human alpha-synuclein gene with the A53T mutation under the prion protein promoter. This model recapitulates key features of PD including progressive neurodegeneration and protein aggregation[1].
The A53T mutation was first identified in the SNCA gene in the Contursi kindred family, a large kindred with autosomal dominant PD. This mutation results in:
| Feature | Details |
|---|---|
| Promoter | Mouse prion protein (MoPrP) |
| Expression | Neuronal, throughout CNS |
| Expression level | 2-4x endogenous mouse α-syn |
| Isoforms | Full-length human A53T α-syn |
| Age | Pathology | Behavior |
|---|---|---|
| 2-4 months | Minimal | Normal |
| 4-8 months | Early aggregation | Subtle deficits |
| 8-12 months | Moderate pathology | Clear motor impairment |
| >12 months | Severe neurodegeneration | Marked phenotype |
| Advantage | Description |
|---|---|
| Genetic relevance | Models familial PD mutation |
| Protein aggregation | Recapitulates Lewy body pathology |
| Progressive model | Age-dependent degeneration |
| Multi-system involvement | Non-motor symptoms present |
| Limitation | Description |
|---|---|
| Overexpression | Not physiological levels |
| Promoter choice | Prion promoter not neuron-specific |
| Species difference | Mouse vs human protein dynamics |
| No sporadic trigger | Pure genetic model |
Used to evaluate:
Investigation of:
| Feature | MPTP | 6-OHDA | A53T |
|---|---|---|---|
| Type | Toxin | Toxin | Genetic |
| Onset | Days | Days | Months |
| Aggregation | No | No | Yes |
| Progressive | No | No | Yes |
| Cost | Low | Medium | High |
Masliah E, et al. Neurodegeneration in transgenic mice with mutant alpha-synuclein. Nat Rev Neurol. 2011. ↩︎